Project Grant HT94252510363
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$1.9M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
This $1,124,825 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to identify novel therapeutic targets for aggressive prostate cancer through induced pluripotent stem cell modeling of BRCA2 mutant prostate tissue. The award, which runs from August 1, 2024 to July 31, 2027, will enable UTHSCSA to conduct innovative scientific...
The University of Texas Health Science Center of San Antonio (UTHSCSA) received a $978,159 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into purinergic receptor antagonist therapeutics for treating metastatic renal cancer from July 1, 2023 through June 30, 2026. As the prime awardee, UTHSCSA will conduct research to develop medical solutions for cancer on the battlefield and...
This Project Grant award, valued at $159,341 and awarded on September 30, 2024, is funded through the Military Medical Research and Development program (CFDA 12.420) of the U.S. Department of the Army Medical Command. The grant supports research at The University of Texas Southwestern Medical Center in Dallas, Texas to target the PARP1 protein as a means of overcoming castration resistance in prostate cancer. The research aims to advance new treatment approaches for this condition, which is a...
The University of Texas Health Science Center at San Antonio (UTHSCSA) received a $508,815 Cooperative Agreement award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to implement and evaluate a patient-centered PTSD treatment program for military personnel. This 4-year award, running from September 1, 2023 to August 31, 2027, will support research to transform healthcare for service members and the public through innovative and...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,560,000.00 to the University of Texas Health Science Center at Houston (UTHealth) to develop drug conjugates of modified LGR4/5/6 ligands for cancer treatment. The funding supports UTHealth's advanced biomedical research focused on transforming healthcare for military service members and the broader public. The award period runs from August 1, 2024...
This federal Project Grant award of $1,854,473.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research by Texas Tech University Health Sciences Center (TTUHSC) to investigate the role of the TBX2 gene in establishing the prostate cancer premetastatic niche in bone. The research aims to advance the understanding of prostate cancer metastasis and develop novel treatment approaches. The award began...
This Project Grant award of $160,167.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a peptide drug conjugate as a bone-targeted therapy for bone metastatic prostate cancer. The award was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, and will fund research activities at the cancer center from September 1, 2023 through August 24, 2024. The project...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The University of Texas Southwestern Medical Center was awarded a $1,376,914 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on the "Modulation Effect of Folate on the Association Between Inorganic Arsenic and Aggressive Prostate Cancer." This 3-year grant, with a start date of September 1, 2023, will support basic, applied, and advanced biomedical research to investigate potential medical solutions...
The federal Project Grant award, valued at $613,125.00 and effective from February 1, 2025 to January 31, 2028, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by the University of Texas MD Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. This advanced cancer research initiative...